Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | DNA polymerase eta, putative | 0.0045 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1062 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0045 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.3135 | 0.2319 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.1062 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.3135 | 0.2319 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.3135 | 0.2319 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 0.1062 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 0.1062 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0045 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 0.1062 | 0.1062 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 0.1062 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.3135 | 0.2319 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1062 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.1062 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 0.1062 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0031 | 0.533 | 0.4775 |
Echinococcus multilocularis | dna polymerase eta | 0.0045 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.3135 | 0.5 |
Brugia malayi | hypothetical protein | 0.0025 | 0.3135 | 0.3135 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.3135 | 0.2319 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0031 | 0.533 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0031 | 0.533 | 0.4775 |
Schistosoma mansoni | DNA polymerase eta | 0.0045 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.3135 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.3135 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 33 uM | Compound was evaluated for the inhibition of cathepsin D at concentration of 4.15 microg/mL | ChEMBL. | No reference |
IC50 (binding) | = 33 uM | Compound was evaluated for the inhibition of cathepsin D at concentration of 4.15 microg/mL | ChEMBL. | No reference |
Inhibition (functional) | = 0 % | Evaluated for the inhibition of fluorescence quenching before the release of 7-amido-4-methylcourmarin (AMC). | ChEMBL. | No reference |
Inhibition (binding) | = 17 % | Compound was evaluated for the inhibition of leucine amino peptidase. | ChEMBL. | No reference |
Inhibition (binding) | = 17 % | Compound was evaluated for the inhibition of leucine amino peptidase. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.